537 related articles for article (PubMed ID: 19841176)
1. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
[TBL] [Abstract][Full Text] [Related]
2. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells.
Twu YC; Gold MR; Teh HS
Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004
[TBL] [Abstract][Full Text] [Related]
3. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
5. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen.
Curtsinger JM; Lins DC; Mescher MF
J Immunol; 1998 Apr; 160(7):3236-43. PubMed ID: 9531279
[TBL] [Abstract][Full Text] [Related]
6. The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death.
Dai Z; Arakelov A; Wagener M; Konieczny BT; Lakkis FG
J Immunol; 1999 Sep; 163(6):3131-7. PubMed ID: 10477579
[TBL] [Abstract][Full Text] [Related]
7. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses.
Baz A; Buttigieg K; Zeng W; Rizkalla M; Jackson DC; Groves P; Kelso A
Vaccine; 2008 May; 26(21):2570-9. PubMed ID: 18420312
[TBL] [Abstract][Full Text] [Related]
8. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
9. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T cell-independent maintenance and expansion of memory CD8+ T cells derived from in vitro dendritic cell activation.
Shi M; Xiang J
Int Immunol; 2006 Jun; 18(6):887-95. PubMed ID: 16621867
[TBL] [Abstract][Full Text] [Related]
11. The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses.
Xiao Z; Curtsinger JM; Prlic M; Jameson SC; Mescher MF
Int Immunol; 2007 Jun; 19(6):733-43. PubMed ID: 17545279
[TBL] [Abstract][Full Text] [Related]
12. Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.
Perret R; Ronchese F
Eur J Immunol; 2008 Oct; 38(10):2886-95. PubMed ID: 18825745
[TBL] [Abstract][Full Text] [Related]
13. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha-induced apoptosis in human naïve and memory CD8+ T cells in aged humans.
Gupta S; Gollapudi S
Exp Gerontol; 2006 Jan; 41(1):69-77. PubMed ID: 16289923
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells.
Apte SH; Baz A; Groves P; Kelso A; Kienzle N
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17475-80. PubMed ID: 18988742
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
17. Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis.
Dayer Schneider J; Seibold I; Saxer-Sekulic N; Paredes BE; Saurer L; Mueller C
Eur J Immunol; 2009 Jul; 39(7):1743-53. PubMed ID: 19551899
[TBL] [Abstract][Full Text] [Related]
18. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness.
Shrikant P; Mescher MF
J Immunol; 1999 Mar; 162(5):2858-66. PubMed ID: 10072534
[TBL] [Abstract][Full Text] [Related]
19. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
20. Protection of CD8+ T cells from activation-induced cell death by IL-18.
Li W; Kashiwamura S; Ueda H; Sekiyama A; Okamura H
J Leukoc Biol; 2007 Jul; 82(1):142-51. PubMed ID: 17400610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
